BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1588042)

  • 1. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
    Lamb CA; Cresswell P
    J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.
    Roche PA; Marks MS; Cresswell P
    Nature; 1991 Dec; 354(6352):392-4. PubMed ID: 1956401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
    Khalil H; Brunet A; Thibodeau J
    J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DR alpha beta dimers released from complexes with invariant chain fail to stimulate alloreactive T cell clones.
    Demotz S
    Eur J Immunol; 1993 Sep; 23(9):2100-8. PubMed ID: 8370392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.
    Newcomb JR; Cresswell P
    J Immunol; 1993 Jan; 150(2):499-507. PubMed ID: 8419482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain.
    Busch R; Vturina IY; Drexler J; Momburg F; Hämmerling GJ
    Eur J Immunol; 1995 Jan; 25(1):48-53. PubMed ID: 7843252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain.
    Arunachalam B; Lamb CA; Cresswell P
    Int Immunol; 1994 Mar; 6(3):439-51. PubMed ID: 8186195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo.
    Newcomb JR; Cresswell P
    J Immunol; 1993 Oct; 151(8):4153-63. PubMed ID: 8409392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia.
    Veenstra H; Jacobs P; Dowdle EB
    Cell Immunol; 1996 Jul; 171(1):68-73. PubMed ID: 8660839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural analysis of invariant chain subsets as a function of their association with MHC class II chains.
    Nguyen QV; Reyes VE; Humphreys RE
    Arch Biochem Biophys; 1995 Feb; 317(1):128-32. PubMed ID: 7872774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
    Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
    J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assembly of major histocompatibility complex class II subunits with invariant chain.
    Neumann J; Koch N
    FEBS Lett; 2005 Nov; 579(27):6055-9. PubMed ID: 16242130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
    Riberdy JM; Newcomb JR; Surman MJ; Barbosa JA; Cresswell P
    Nature; 1992 Dec; 360(6403):474-7. PubMed ID: 1448172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular transport of class II MHC molecules directed by invariant chain.
    Lotteau V; Teyton L; Peleraux A; Nilsson T; Karlsson L; Schmid SL; Quaranta V; Peterson PA
    Nature; 1990 Dec; 348(6302):600-5. PubMed ID: 2250716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invariant chain influences post-translational processing of HLA-DR molecules.
    Schaiff WT; Hruska KA; Bono C; Shuman S; Schwartz BD
    J Immunol; 1991 Jul; 147(2):603-8. PubMed ID: 2071896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.